It is known as a targeted therapy because it particularly targets the CD38 which can be overexpressed about the multiple myeloma cells. Daratumumab is from a class of medicines referred to as CD38 monoclonal antibodies. DARZALEX® is specified as an intravenous (IV) infusion after dilution at sixteen mg/kg of genuine https://danielr591kvb4.mdkblog.com/profile